Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Companies Ink siRNA Deals

by Lisa M. Jarvis
April 5, 2010 | A version of this story appeared in Volume 88, Issue 14

More companies have plans to develop small-interfering-RNA-based drugs. Dicerna Pharmaceuticals and Ipsen will work together to improve the delivery of siRNA. The goal is to make novel conjugates of Dicerna's dicer-substrate siRNA molecules and Ipsen's peptide-targeting vectors to develop therapeutics for oncology and endocrinology. In a separate deal, Silence Therapeutics and Dainippon Sumitomo Pharma have expanded an siRNA delivery pact they initiated in August. The new deal adds to the number of disease targets that Dainippon can access through Silence's siRNA stabilization technology and its lipid delivery technology.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.